reference/18889552

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18889552

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	6243
issn	0250-7005 1791-7530
issueIdentifier	11
pageRange	6235-6243
publicationName	Anticancer Research
startingPage	6235
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_dcbd0e819edfe5623bf284071afca51e http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_76fa702acc2090759d6916abc50b2a3a http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9d50f771df3f48b6fe60af06e1790826 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_2bb4658c80dbc0d82d9883ae789beb0a http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d083af992003e7a623feba37e9508ff4
bibliographicCitation	Yang Y, Li X, Mamouni K, Kucuk O, Wu D. Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer. Anticancer Res. 2017 Nov;37(11):6235–43. doi: 10.21873/anticanres.12074. PMID: 29061806.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d4b5936d7f7ff6af6efc9cc2d846b1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5e11d5de60c5ef4e5e046d0091722eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89718696b7066523167e2669fd930250 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd5f91b483971c2320383806f58edaf6
date	2017-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.21873/anticanres.12074 https://pubmed.ncbi.nlm.nih.gov/29061806
isPartOf	https://portal.issn.org/resource/ISSN/0250-7005 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/592 https://portal.issn.org/resource/ISSN/1791-7530
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer
discusses	http://id.nlm.nih.gov/mesh/M0010537 http://id.nlm.nih.gov/mesh/M0024116 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0577955 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0002327 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0016576
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D043823Q000494 http://id.nlm.nih.gov/mesh/D015735Q000494 http://id.nlm.nih.gov/mesh/D010669Q000031 http://id.nlm.nih.gov/mesh/D001859Q000188 http://id.nlm.nih.gov/mesh/D064129Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D001859Q000556 http://id.nlm.nih.gov/mesh/D014407 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D064129Q000473 http://id.nlm.nih.gov/mesh/D017209Q000187 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D000970Q000494 http://id.nlm.nih.gov/mesh/D023041 http://id.nlm.nih.gov/mesh/D009570 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D006727Q000494 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D001549 http://id.nlm.nih.gov/mesh/D049109Q000187 http://id.nlm.nih.gov/mesh/D010669Q000494
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID55245 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8

Total number of triples: 69.